- Diagnostic Différentiel
Drug Information for FEMCON Fe (norethindrone and ethinyl estradiol tablets,chewable and ferrous fumarate tablets) 0.4 mg / 35 mcg (Warner Chilcott (US), LLC): CLINICAL PHARMACOLOGY
- CLINICAL PHARMACOLOGY
- INDICATIONS AND USAGE
- INFORMATION FOR THE PATIENT
- ADVERSE REACTIONS
- NONCONTRACEPTIVE HEALTH BENEFITS
- DOSAGE AND ADMINISTRATION
- HOW SUPPLIED
- PATIENT BRIEF SUMMARY
- DETAILED PATIENT PACKAGE INSERT
- PRINCIPAL DISPLAY PANEL
- Liens externes liés à FEMCON Fe (norethindrone and ethinyl estradiol tablets,chewable and ferrous fumarate tablets) 0.4 mg / 35 mcg (Warner Chilcott (US), LLC)
Combination oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation).
Ethinyl estradiol and norethindrone are rapidly absorbed with maximum plasma concentrations occurring within 2 hours after FEMCON Fe administration (see Table 1). Norethindrone appears to be completely absorbed following oral administration; however, it is subject to first-pass metabolism resulting in an absolute bioavailability of approximately 65%. Large intersubject variability is reflected in a 3- to 5-fold variation in norethindrone bioavailability. Ethinyl estradiol bioavailability is approximately 43% due to small-intestinal and hepatic first-pass metabolism.
Table 1. Mean ±SD Pharmacokinetic Parameters Following Single Dose Administration of FEMCON Fe in Healthy Female Subjects Under Fasting Conditions. Norethindrone/Ethinyl Estradiol tmax (h) Cmax (pg/mL) AUC0-8 (pg•h/mL) t1/2 (h) Norethindrone 0.4 mg
1.24 ± 0.40n = 26
4210.6 ± 1628.8 18034.9 ± 7852.9n = 25 8.6 ± 3.7 Ethinyl Estradiol 35 mcg
1.44 ± 0.33
131.4 ± 34.2
1065.8 ± 276.2
17.1 ± 4.4
Cmax = maximum plasma concentration; tmax = time to reach Cmax; AUC = area under the curve; t1/2 = elimination half life.
Effect of Food. Single-dose administration of FEMCON Fe tablets with food decreased the maximum norethindrone and ethinyl estradiol concentration by 53% and 47%, respectively; the extent of norethindrone and ethinyl estradiol absorption (AUC values) was not affected by food administration.
Norethindrone is 36% bound to sex hormone-binding globulin (SHBG) and 61% bound to albumin. Ethinyl estradiol is not bound to SHBG but is highly (98.5%) bound to albumin. Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg.
Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation; less than 5% of a norethindrone dose is excreted unchanged; greater than 50% and 20-40% of a dose is excreted in urine and feces, respectively. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites.
Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol, and glucuronides predominate in urine. The primary oxidative metabolite is 2-hydroxy-ethinyl estradiol which is formed by the CYP3A4 isoform of cytochrome P450.
Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg). Ethinyl estradiol and norethindrone are excreted in both urine and feces, primarily as metabolites. Ethinyl estradiol is excreted in urine and feces as glucuronides and sulfates, and about 28-43% undergoes enterohepatic circulation. The mean terminal elimination half-lives of norethindrone and ethinyl estradiol following single dose administration of FEMCON Fe are approximately 9 hours and 17 hours, respectively.
Race. The effect of race on the disposition of norethindrone and ethinyl estradiol after FEMCON Fe administration has not been evaluated.
Renal Insufficiency. The effect of renal disease on the disposition of norethindrone and ethinyl estradiol after FEMCON Fe administration has not been evaluated. In premenopausal women with chronic renal failure undergoing peritoneal dialysis who received multiple doses of an oral contraceptive containing ethinyl estradiol and norethindrone, plasma ethinyl estradiol concentrations were higher and norethindrone concentrations were unchanged compared to concentrations in premenopausal women with normal renal function.
Hepatic Insufficiency. The effect of hepatic disease on the disposition of norethindrone and ethinyl estradiol after FEMCON Fe administration has not been evaluated. However, ethinyl estradiol and norethindrone may be poorly metabolized in patients with impaired liver function.
See PRECAUTIONS section—DRUG INTERACTIONS
- Drug Information Provided by National Library of Medicine (NLM).